SEC Comment Letter for Accelerate Diagnostics, Inc (AXDX) (CIK 0000727207) — Feb 8, 2022
Accelerate Diagnostics, Inc (AXDX) (CIK 0000727207)
Date: Feb. 8, 2022 · CIK: 0000727207 · Accession: 0000000000-22-001585
AI Filing Summary & Sentiment
File numbers found in text: 333-262494
Letter
United States securities and exchange commission logo February 8, 2022 Jack Phillips President and Chief Executive Officer Accelerate Diagnostics, Inc. 3950 South Country Club Road, Suite 470 Tucson, AZ 85714 Re:Accelerate Diagnostics, Inc. Registration Statement on Form S-3 Filed February 3, 2022 File No. 333-262494 Dear Mr. Phillips: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dillon Hagius at 202-551-7967 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua A. Schneiderman
Show Raw Text
United States securities and exchange commission logo
February 8, 2022
Jack Phillips
President and Chief Executive Officer
Accelerate Diagnostics, Inc.
3950 South Country Club Road, Suite 470
Tucson, AZ 85714
Re:Accelerate Diagnostics, Inc.
Registration Statement on Form S-3
Filed February 3, 2022
File No. 333-262494
Dear Mr. Phillips:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dillon Hagius at 202-551-7967 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua A. Schneiderman